What is the health economic evidence profile for treating chronic heart failure?
The health economic evidence profile for treating chronic heart failure is outlined in Table 55 of NICE 2018. It includes an incremental cost-effectiveness ratio (ICER) of 20,000/30,000 per quality-adjusted life years (QALY) gained, a within-trial analysis of the FAIR-HF trial which compared no iron treatment with iron repletion with ferric carboxymaltose IV bolus injection, and a 24-week follow-up. Univariate and probabilistic sensitivity analyses were undertaken, with the frequency and duration of hospitalisation, QALY difference, and cost of hospital day being the most influential parameters. None of the parameters tested resulted in an ICER above 20,000 per QALY gained. 